The 19th Health Industry Ecology Conference, known as the 2026 Xipu Summit, concluded its six-day run in Boao, Hainan, on August 16. As the premier annual event for China's health sector, this year's gathering centered on the theme "Entering the AI Era: Paradigm Revolution and Path Choices for the Health Industry," bringing together industry-wide forces to assess ultimate trends and chart a course for innovation. Facing a critical inflection point marked by slowing industry growth, deep regulatory restructuring, and pervasive AI integration, the 2026 Xipu Summit moved beyond incremental improvements, focusing on a fundamental rethinking of the industry's underlying logic. It delivered a systematic annual report on the intelligent transformation and high-quality development of the health sector, setting a new direction for the industry to navigate cyclical challenges and achieve long-term growth.

In a keynote report, Wu Han, Chairman of Sinohealth Technology and Chairman of the Xipu Summit, offered a key assessment: the health industry has moved beyond the era of linear, experience-driven growth and entered a new phase of exponential, algorithm-driven evolution. He argued that the current change is a fundamental paradigm shift, not a mere optimization. The report clarified the industry's incremental logic and alleviated cyclical anxiety from three perspectives: boundary reconstruction, decision-making enhancement, and trust rebuilding. To address the industry's lack of methods and systems for AI implementation, the summit unveiled a four-dimensional transformation framework covering data, scenarios, organizations, and compliance. This framework provides a clear, actionable path for enterprises to upgrade intelligently, pushing AI from conceptual testing to tangible industrial empowerment. Leveraging its deep data accumulation across the industrial chain, Sinohealth released several major reports predicting the domestic health industry will reach a scale of 16 trillion yuan by 2030 and identifying five key sectors for strategic investment: innovative drugs, high-end intelligent medical devices, AI-powered healthcare, the silver economy, and out-of-hospital traditional Chinese medicine. The reports accurately delineated industry contraction and growth patterns, delivering the core judgment that "what is being eliminated are companies, not the industry itself," and offering authoritative strategic guidance for the entire sector to navigate cycles. A parallel report on the retail sector directly addressed operational pain points, providing a roadmap for AI-driven digital transformation, serving as a key reference for retail enterprises.

As the industry's premier annual platform for strategic announcements and authoritative voices, the summit attracted over 60,000 participants from across the full value chain, including pharmaceuticals, commercial and retail, innovative drugs and devices, AI technology, and capital. This gathering of academic authorities, industry leaders, capital giants, policy experts, and technology pioneers solidified the summit's role as a top-tier platform for dialogue, releases, and resource sharing. The event featured a lineup of high-level think tanks, including the inaugural "Boao Dialogue on Life Sciences and Health Industry," a landmark IP. Academician Shi Yigong from the Chinese Academy of Sciences led a deep dive into the disruptive impact of protein design technology on the macromolecular drug sector, anchoring the direction of future scientific research. Meanwhile, representatives from Insilico Medicine, Tencent Health, the China Academy of Information and Communications Technology (CAICT), and other tech and industry players gathered in Boao for high-level discussions on AI drug discovery, digital healthcare implementation, industry compliance evolution, and paradigm shifts, breaking down barriers between research and industry. This convergence of cutting-edge ideas, core technologies, and industry judgments confirmed the consensus that AI is transitioning from a conceptual hotspot into a core industrial productivity driver.

A major highlight of the summit was the simultaneous execution of over 30 major brand launches and signing ceremonies, making it a central stage for the industry's annual restructuring. Domestic leaders like Tasly, Innovent Biologics, Tongrentang, Yunnan Baiyao, China Resources Jiangzhong, and Dong'e Ejiao unveiled their annual plans for innovation, channel upgrades, and brand revitalization. Foreign giants including Roche, AstraZeneca, Pfizer, and Novo Nordisk continued to deepen their presence in the Chinese market, launching new products and building ecosystems. In the digital health space, Sinohealth Technology and Tencent Health signed a major agreement to jointly launch an AI-powered pharmacy health service solution. Over 100 AI tech companies, including Baidu, Yingdao RPA, and Haici Technology, showcased their achievements in medical digitalization, demonstrating new commercial scenarios for AI in healthcare. The simultaneous presence and synchronized evolution of leading domestic and international brands reinforced the summit's status as the industry's premier annual platform for strategic announcements and value expression. The concurrently running 20,000-square-meter brand exhibition hall featured benchmark companies from home and abroad, such as Guangzhou Pharmaceutical, Hengrui Medicine, CSPC Pharmaceutical, Pian Zai Huang, Cofoe Medical, and Haleon, showcasing cutting-edge technologies, major new products, and digital solutions, thereby releasing the industry's brand potential and innovative vitality.

The summit employed a comprehensive ecological matrix to break down barriers between upstream and downstream sectors, creating a full-cycle closed loop encompassing trend discussions, technology implementation, resource matching, and brand empowerment. Nine core summits precisely targeted key areas such as AI digitalization, innovative drug commercialization, out-of-hospital markets, the silver economy, and health consumer goods. They focused on real industry pain points, addressing issues like the ineffective application of AI, weak terminal transformation, and difficulties in commercializing innovation. In terms of industrial ecosystem building, the summit guided positive development through diverse brand activities. The "Entrepreneurial Spirit Night" focused on long-termism and corporate mission, fostering industry consensus. A series of authoritative top 100 and innovative brand lists continued to set industry benchmarks, guiding the sector away from inefficient competition towards high-quality development. These were complemented by over 100 vertical satellite sessions, high-end BD (Business Development) matchmaking, and closed-door CEO roundtables, building an efficient, collaborative platform for win-win outcomes across the entire industry chain.

Distinguishing itself from conventional commercial and technical conferences, this year's Xipu Summit established a core humanistic essence of "technology for good" and "life-first" through its theme film "Body Temperature," top-level concepts, closing remarks, and official thank-you letters. The summit made it clear that AI is a tool for industrial upgrade, not the ultimate goal. Amidst the wave of comprehensive algorithmic and digital transformation, the health industry must uphold its reverence for life and initial service commitment. It aims to preserve a humanistic space for technological development and business growth, constructing a sustainable development model where "technology is the body, and the original intention is the soul," injecting a warm and lasting value into the rapidly evolving industry.